Sat, Apr 19, 2014, 5:54 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Rosetta Genomics, Ltd. Message Board

bio7mm 19 posts  |  Last Activity: Apr 15, 2014 11:12 AM Member since: May 25, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Perhaps that is why they are reducing their own staff in Boston? Also they expressed disappointment in siRNA targets, but the beauty of Marina is that they have the broadest oligo drug delivery toolkit in the industry! I won't sell my MRNA stock for 20 years!

  • And read the very positive story on ProNAi's success with the trials and plans to go public. I like this comment. What does it mean for Marina?

    The company will use its funding to conduct more human trials on its lead product, which has the working name of PNT2258, and to get two other cancer-fighting compounds into trials.

    Wish we got credit with these sentences, but it's positive for SMARTICLES:

    Messmann said the key to PNT2258's success is a fatty coating that limits toxicity. Most cancer drugs are so toxic that they can't be put into the bloodstream for fear of causing systemic damage. They are put directly into tumors, but they then miss other cancer cells that may be circulating in the system.

    The fatty liposome coating, designed by Wendi Rodrigueza, a former scientist at Pfizer Inc. now at ProNAi, also keeps the drug from being attacked by white blood cells and later helps the drug penetrate the surface of tumors and cancer cells when it finds them.

    Really enjoyed the stories on the patients:

    Four of the 12 are now in remission and 10 had their tumors shrink. One of those in remission is a woman in her late 60s who had tumors in her abdomen, neck and chest. Another was a 40-year-old man whose tumor was so aggressive it had fractured his spine and packed his bone marrow with cancer cells.

    Both had life expectancies of between six and 12 months before treatment. After six months of treatment, both appear to be disease free. And, unlike chemotherapy and radiation, PNT2258 appears to have few side effects.

    Read the whole story. It is amazing and gives you a hint at the excitement to come with Marina Biotech.

  • Thanks to Copphiggins and Farmer for the kind words. That April 1, 2012 post was a dream of mine that came true! Yes I am looking out much further than 2 years. There are so many undruggable targets available for Marina's broad Nucleic Acid capabilities that I think they can have a multi billion dollar market cap in the next 3-5 years once they start generating Phase 2 data. Michael French is a visionary and sees the market cap of companies like Alexion that target rare diseases. We do have the best overall Nucleic Acid drug delivery toolkit in the industry. Rosetta can find better than any other company which microRNAs are up or down regulated with the three diseases mentioned in the PR yesterday. Wish I could post more but my day job responsibities have increased. Hopefully some day soon I can become a full time biotech venture capitalist! I do read our Board frequently and look forward to good news over the next year and beyond.

  • Marina has a much broader oligo drug delivery toolkit than Arrowhead. Based on values the market is placing on RNAi companies today, we should be 1000% higher than $22 million market cap.

  • And view/listen to the Apr. 26, 2012 video where he talks about the new antigen Tapimmune has access to that no other company has access to and how when combined with TAP it may provide a
    Superior solution for many HER2/neu breast cancer patients.Keith Knutson also believes it has strong potential for ovarian cancer.

  • Reply to

    Why MRNA has huge potential

    by info4board Feb 4, 2014 1:44 PM
    bio7mm bio7mm Feb 9, 2014 4:45 PM Flag

    I completely agree.

  • Reply to

    ok, i am in and we can take off

    by juststeve55 Feb 7, 2014 2:24 PM
    bio7mm bio7mm Feb 9, 2014 4:32 PM Flag

    All major investors have known about it for weeks. Apparently there is no major selling. Actually there has been net buying interest as the price has been rising. RS by itself has no effect on the market value of the company. You still own shares at the same market cap.

  • Reply to

    Why MRNA has huge potential

    by info4board Feb 4, 2014 1:44 PM
    bio7mm bio7mm Feb 9, 2014 4:19 PM Flag

    I agree completely.

  • Reply to

    ok, i am in and we can take off

    by juststeve55 Feb 7, 2014 2:24 PM
    bio7mm bio7mm Feb 9, 2014 4:12 PM Flag

    It was explained weeks ago in their SEC filings. All major investors in TPIV have known about the RS since then or before. Apparently none of the major investors are selling. There is net buying interest pushing up the stock price. Who's buying? Anybody's guess.

  • Reply to

    Google "YouTube Tapimmune Keith Knutson"

    by bio7mm Feb 6, 2014 11:19 PM
    bio7mm bio7mm Feb 8, 2014 11:54 PM Flag

    Listen to the end of the video when Keith mentions breast cancer and ovarian cancer. Sounds like ovarian cancer might be the next target after breast cancer?

  • And listen to his description of the project he is working on with Tapimmune. Scroll
    down to view other videos from Glynn Wilson our CEO. He does a great job describing the Tapimmune advantages.

  • Because I think that is possible in the next 10 years! I will literally make millions when that occurs.

  • bio7mm bio7mm Jan 28, 2014 9:34 AM Flag

    Look at the slide in the recent presentation given by French in San Fran. That shows a comparison of oligo companies and their chemistries. Marina has the broadest in the industry. I believe in Michael French's vision that Big Pharma will want to partner with firms that have many options for silencing genes. Marina is the only one with a double strand and single strand RNA in the clinic. Unfortunately we had to spend all our cash over the last 5 years to acquire those assets but it will pay off in the future. Still very early in this game. Marina has the best long term vision in my opinion.

  • Reply to

    Mayo Clinic contacted Tapimmune to work with them!

    by bio7mm Jan 25, 2014 2:28 PM
    bio7mm bio7mm Jan 27, 2014 10:26 PM Flag

    And they are valued at $519 million for technology that doesn't accomplish as much as our technology.

  • Impressive list of competitive advantages from a PR when Tapimmune was GeneMax Corp on Sept. 9, 2003. Just shows how long it takes these biotechs to get the stars aligned but I think TPIV is getting ready to roll:

    Based on cancer incidence data collected for the year 2000 from a Lyon, IARCPress document of 2001, the Company's TAP cancer technology, if successful, may form a relevant immunotherapy for 60%-70% of all new incidences of cancer in the US, Japan, and the four major European markets. The competitive advantages include: efficacy against secondary cancerous growths elsewhere in the body, no restrictions on the patient's HLA type, no restrictions regarding the genetics of the tumors, and non-toxicity to normal cells. The technology is complementary and synergistic with all other immunotherapies dependent on cytotoxic T cell killing and also has the potential to enable a variety of tumor antigen vaccines.

  • The market caps of both companies will be very close in the future. I believe Marina has a better toolkit than Alnylam. Battle of the RNAI Titans in Cambridge Mass in the next 5-10 years!

  • On May 24, 2010, Tapimmune sold $1.5 million in Secured Convertible Notes. They were issued with warrants to buy common shares but I don't think they created dilution the day they received the $1.5 million from investors. If mgmt plays it right, they do the reverse split, issue some great news to get the price up over $5 and then secure only the funding needed through a debt offering to complete some trials. Maybe the future exercise price is over $5! Remember, when the reverse split takes place Wilson and the senior leadership team get their preferred shares converted to common shares. Wouldn't you do that if you thought the price of the common shares had a really good chance of rising? Then institutions will pile into it once it gets above $5! This company's market cap should be $100 million based on potential alone. They are addressing multi billion dollar markets with a superior product!

  • Mayo Clinic contacted Tapimmune to work with them back in June 2010! Google "Tapimmune evoking aggressive response by the immune system" It's an article written by ME Garza on Apr. 6, 2011 and provides excellent background info on the collaboration between the two entities. A must read.

  • Once your preferred shares become common shares your interests will be aligned with ours. Don't issue any additional shares for capital. License something for cash in a non core area.
    Let's get the price back up to 25 cents where it was in April 2012!

3.80-0.01(-0.26%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Rayonier Inc.
NYSEThu, Apr 17, 2014 4:03 PM EDT